Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant
•We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE.•Adjuvanted vaccine was substantially more immunogenic at all dose levels than the unadjuvanted vaccine.•Even at the lowest dose of vaccine administered, serum HAI antibody responses of ≥1:40 were seen...
Saved in:
| Published in | Vaccine Vol. 31; no. 48; pp. 5760 - 5765 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
19.11.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | •We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE.•Adjuvanted vaccine was substantially more immunogenic at all dose levels than the unadjuvanted vaccine.•Even at the lowest dose of vaccine administered, serum HAI antibody responses of ≥1:40 were seen in 72% of subjects.•GLA/SE is an effective adjuvant for recombinant H5 HA.•Baculovirus-expressed HA vaccine has promise for pandemic preparedness as well.
Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE).
Healthy adults 18–49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135μg or 45μg, or rHA 45μg, 15μg, 7.5μg or 3.8μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42.
392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50–70% of rHA+GLA/SE recipients and 4–9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135μg and 45μg groups, and 82%, 75%, 66%, and 72% in those receiving 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE groups, respectively.
rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. |
|---|---|
| AbstractList | Background Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). Methods Healthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135[micro]g or 45[micro]g, or rHA 45[micro]g, 15[micro]g, 7.5[micro]g or 3.8[micro]g with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. Results 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers >=1:40 were 32% and 15% in the unadjuvanted 135[micro]g and 45[micro]g groups, and 82%, 75%, 66%, and 72% in those receiving 45[micro]g, 15[micro]g, 7.5[micro]g, or 3.8[micro]g with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45[micro]g, 15[micro]g, 7.5[micro]g, or 3.8[micro]g with GLA/SE groups, respectively. Conclusions rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. •We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE.•Adjuvanted vaccine was substantially more immunogenic at all dose levels than the unadjuvanted vaccine.•Even at the lowest dose of vaccine administered, serum HAI antibody responses of ≥1:40 were seen in 72% of subjects.•GLA/SE is an effective adjuvant for recombinant H5 HA.•Baculovirus-expressed HA vaccine has promise for pandemic preparedness as well. Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). Healthy adults 18–49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135μg or 45μg, or rHA 45μg, 15μg, 7.5μg or 3.8μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50–70% of rHA+GLA/SE recipients and 4–9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135μg and 45μg groups, and 82%, 75%, 66%, and 72% in those receiving 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE groups, respectively. rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE).Healthy adults 18–49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135μg or 45μg, or rHA 45μg, 15μg, 7.5μg or 3.8μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42.392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50–70% of rHA+GLA/SE recipients and 4–9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135μg and 45μg groups, and 82%, 75%, 66%, and 72% in those receiving 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE groups, respectively.rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/lndonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+ GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. Highlights • We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE. • Adjuvanted vaccine was substantially more immunogenic at all dose levels than the unadjuvanted vaccine. • Even at the lowest dose of vaccine administered, serum HAI antibody responses of ≥1:40 were seen in 72% of subjects. • GLA/SE is an effective adjuvant for recombinant H5 HA. • Baculovirus-expressed HA vaccine has promise for pandemic preparedness as well. Background: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). BACKGROUND: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). METHODS: Healthy adults 18–49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135μg or 45μg, or rHA 45μg, 15μg, 7.5μg or 3.8μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. RESULTS: 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50–70% of rHA+GLA/SE recipients and 4–9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135μg and 45μg groups, and 82%, 75%, 66%, and 72% in those receiving 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45μg, 15μg, 7.5μg, or 3.8μg with GLA/SE groups, respectively. CONCLUSIONS: rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE).BACKGROUNDExpression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE).Healthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135 μg or 45 μg, or rHA 45 μg, 15 μg, 7.5 μg or 3.8 μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42.METHODSHealthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135 μg or 45 μg, or rHA 45 μg, 15 μg, 7.5 μg or 3.8 μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42.392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135 μg and 45 μg groups, and 82%, 75%, 66%, and 72% in those receiving 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE groups, respectively.RESULTS392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135 μg and 45 μg groups, and 82%, 75%, 66%, and 72% in those receiving 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE groups, respectively.rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control.CONCLUSIONSrHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a rapid response to the emergence of new, pandemic strains. We evaluated the safety and immunogenicity of rHA vaccine (H5/Indonesia/5/05) produced in SF+ insect cells using a baculovirus expression vector system (BEVS). The rHA vaccine was tested with and without the adjuvant glucopyranosyl lipid A/stable emulsion (GLA/SE). Healthy adults 18-49 were randomized to two IM doses on Days 0 and 21 of placebo; unadjuvanted rHA 135 μg or 45 μg, or rHA 45 μg, 15 μg, 7.5 μg or 3.8 μg with GLA/SE. A pioneer group was monitored through Day 42 before randomizing remaining subjects. H5-specific antibody was determined by hemagglutination inhibition (HAI) and microneutralization (MN) on Days 0, 21 and 42. 392 subjects were randomized, of whom 380 (97%) received two doses and 386 (98%) completed 12 months of follow-up. Injection site pain and tenderness were seen in 50-70% of rHA+GLA/SE recipients and 4-9% of rHA alone and placebo recipients, but most complaints were mild to moderate in intensity. After two doses, the proportions of subjects with HAI titers ≥1:40 were 32% and 15% in the unadjuvanted 135 μg and 45 μg groups, and 82%, 75%, 66%, and 72% in those receiving 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE. The geometric mean titers (GMTs) of HAI antibody on Day 42 were 128, 95, 69, and 72 in the 45 μg, 15 μg, 7.5 μg, or 3.8 μg with GLA/SE groups, respectively. rHA GLA/SE was well tolerated and immunogenic in healthy adults, and GLA/SE substantially improved the serum antibody response. rHA expressed using BEVS recombinant DNA platform technology represents a promising strategy for pandemic control. |
| Author | Izikson, Ruvim Reed, Steven Goldenthal, Karen L. Treanor, John J. Patriarca, Peter Essink, Brandon Hull, Steven Kohberger, Robert Dunkle, Lisa M. |
| Author_xml | – sequence: 1 givenname: John J. surname: Treanor fullname: Treanor, John J. email: john_treanor@urmc.rochester.edu organization: University of Rochester School of Medicine, Rochester, NY, United States – sequence: 2 givenname: Brandon surname: Essink fullname: Essink, Brandon organization: Meridian Clinical Research, Omaha, NE, United States – sequence: 3 givenname: Steven surname: Hull fullname: Hull, Steven organization: Vince and Associates Clinical Research, Overland Park, KS, United States – sequence: 4 givenname: Steven surname: Reed fullname: Reed, Steven organization: Immune Design Corporation, Seattle, WA, United States – sequence: 5 givenname: Ruvim surname: Izikson fullname: Izikson, Ruvim organization: Protein Sciences Corporation, Meriden, CT, United States – sequence: 6 givenname: Peter surname: Patriarca fullname: Patriarca, Peter organization: Biologics Consulting, Inc., Bethesda, MD, United States – sequence: 7 givenname: Karen L. surname: Goldenthal fullname: Goldenthal, Karen L. organization: Independent Consultant, Bethesda, MD, United States – sequence: 8 givenname: Robert surname: Kohberger fullname: Kohberger, Robert organization: Independent Consultant, Stamford, CT, United States – sequence: 9 givenname: Lisa M. surname: Dunkle fullname: Dunkle, Lisa M. organization: Protein Sciences Corporation, Meriden, CT, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27949104$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/24075920$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk91q3DAQhU1paX7aR2grKIWE4t2RbckypS0hpEkg0Is00DuhlccbbWVpa9kbts_ZB6qcTQgEyubGMvI3Z45HR3vJc-cdJskbChMKlE8Xk5XS2jicZEDzCYgJ8OJZsktFmacZo-J5sgsZL9KCws-dZC-EBQCwnFYvk52sgJJVGewmf09Wyg6qN94R35CgGuzXRLmamLYdnJ-jM9rErfixQ-3bmXHK9cS4xg7o_ihyja2az-3QG2ccOThj03NXR6_BqCmwaRabHpLGd-1gVY81uTH99W2D8cUPPVEk9GpmkXhjU-PSm4h1BCMfRlfau16N2nMSu2i_XHfK-bC2qTVLU5MjcnB58vH04uiQqHoxrKK7V8mLRtmAr-_W_eTq28mP47P04vvp-fHRRao5Y306oyVjGjCveMUBm_hEVupSCxCq4RpBcF5UM1YKzSuEWaG5UJALXpa0EJDvJwcb3WXnfw8YetmaoNFa5dAPQVIeUQrAxXaUUV4yzvP8KWiW55yV2Xa0KKqMC8FG1feP0IUfOhfHEwULIXKalzxSb--oYdZiLZedaVW3lveBicCHO0AFrWwTz0Kb8MCVVVFRKCL3acPpzofQYSNjim5j1nfKWElBjjGWC3kXYznGWIKQMcaxmj2qvm-wre7dpq5RXqp5F51dXUaAAdCyorc_-HVDYMzFymAngzboNNYmxruXtTdbe3x5pKBtjGccxi9cY3iYqgyZBHk5XsLxDtIcaHQwWvj8f4EnGPgHfPpBSw |
| CODEN | VACCDE |
| CitedBy_id | crossref_primary_10_1016_j_ebiom_2019_03_010 crossref_primary_10_1016_j_vaccine_2015_10_137 crossref_primary_10_1007_s00262_019_02331_x crossref_primary_10_1016_j_coi_2016_06_007 crossref_primary_10_1016_j_coi_2017_06_006 crossref_primary_10_1016_j_drugalcdep_2019_05_016 crossref_primary_10_3389_fimmu_2018_00295 crossref_primary_10_1111_imr_12662 crossref_primary_10_1016_j_ajps_2014_06_002 crossref_primary_10_3390_diseases11040177 crossref_primary_10_1038_s41541_017_0043_3 crossref_primary_10_1016_j_coph_2018_03_014 crossref_primary_10_1371_journal_pntd_0005951 crossref_primary_10_1016_j_vaccine_2016_06_081 crossref_primary_10_1016_j_vaccine_2015_10_027 crossref_primary_10_3390_vaccines9030296 crossref_primary_10_1002_biot_201400438 crossref_primary_10_1016_j_smim_2018_10_004 crossref_primary_10_1371_journal_pntd_0007083 crossref_primary_10_1016_j_heliyon_2024_e24662 crossref_primary_10_1189_jlb_4MR0716_290R crossref_primary_10_3389_fimmu_2019_02006 crossref_primary_10_1016_j_vaccine_2019_05_026 crossref_primary_10_1128_IAI_02980_14 crossref_primary_10_1038_s41571_019_0319_9 crossref_primary_10_1080_21645515_2024_2347019 crossref_primary_10_4049_jimmunol_1600993 crossref_primary_10_1016_j_vaccine_2019_02_002 crossref_primary_10_1016_j_cyto_2017_08_009 crossref_primary_10_1080_21645515_2017_1415684 crossref_primary_10_1007_s12016_018_8694_z crossref_primary_10_1038_s41573_019_0056_x crossref_primary_10_1002_ijc_29885 crossref_primary_10_1039_D2CS00848C crossref_primary_10_1093_infdis_jiw231 crossref_primary_10_3389_fimmu_2014_00316 crossref_primary_10_1016_j_carres_2020_108152 crossref_primary_10_1038_cti_2015_6 crossref_primary_10_1038_s41541_021_00418_0 crossref_primary_10_1039_D0CB00165A crossref_primary_10_4049_jimmunol_1701604 crossref_primary_10_1016_j_vaccine_2023_08_009 crossref_primary_10_3389_fimmu_2023_1155200 crossref_primary_10_1016_j_ejpb_2015_05_023 crossref_primary_10_1016_j_addr_2021_01_002 crossref_primary_10_1016_j_vaccine_2014_06_057 crossref_primary_10_1080_21645515_2020_1777822 crossref_primary_10_1016_j_vaccine_2016_12_053 crossref_primary_10_1371_journal_pone_0131652 crossref_primary_10_3390_vaccines2020323 crossref_primary_10_1016_j_ijpharm_2015_03_028 crossref_primary_10_1016_j_vaccine_2023_07_061 crossref_primary_10_1371_journal_pone_0107764 crossref_primary_10_1038_srep19570 crossref_primary_10_1038_s41541_021_00391_8 crossref_primary_10_3389_fimmu_2022_878943 crossref_primary_10_3390_vaccines9101074 crossref_primary_10_1186_s13568_016_0179_y crossref_primary_10_1038_s41541_022_00467_z crossref_primary_10_2217_fvl_15_75 crossref_primary_10_1016_j_intimp_2016_03_028 crossref_primary_10_1371_journal_pntd_0004431 crossref_primary_10_1586_14760584_2014_938641 crossref_primary_10_3389_fimmu_2018_00381 |
| Cites_doi | 10.1016/j.vaccine.2011.01.039 10.1016/j.vaccine.2009.10.037 10.1001/jama.297.14.1577 10.1086/605608 10.1126/science.1213362 10.1016/j.jip.2011.05.003 10.1086/600035 10.1016/j.vaccine.2011.07.128 10.1016/j.vaccine.2005.11.005 10.1093/infdis/jir191 10.1371/journal.pone.0016333 10.1086/503050 10.1016/j.vaccine.2009.07.081 10.1086/527489 10.1056/NEJMoa040419 10.1038/nature10831 10.1086/590916 10.1086/592172 10.1007/s10875-010-9490-6 10.1016/j.vaccine.2010.02.050 10.1056/NEJMoa055778 10.1128/CVI.00368-08 10.1086/599992 10.1126/science.1222526 10.1016/S0264-410X(00)00395-9 10.1093/infdis/jir328 |
| ContentType | Journal Article |
| Copyright | 2013 2015 INIST-CNRS Copyright © 2013. Published by Elsevier Ltd. Copyright Elsevier Limited Nov 19, 2013 |
| Copyright_xml | – notice: 2013 – notice: 2015 INIST-CNRS – notice: Copyright © 2013. Published by Elsevier Ltd. – notice: Copyright Elsevier Limited Nov 19, 2013 |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 |
| DOI | 10.1016/j.vaccine.2013.08.064 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) ProQuest Nursing & Allied Health Database (NC LIVE) Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database ProQuest Research Library (NC LIVE) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | Research Library Prep AGRICOLA AIDS and Cancer Research Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 5765 |
| ExternalDocumentID | 3386318561 24075920 27949104 10_1016_j_vaccine_2013_08_064 US201500179176 S0264410X13011766 1_s2_0_S0264410X13011766 |
| Genre | Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | Asia South east Asia Indonesia |
| GeographicLocations_xml | – name: Indonesia |
| GrantInformation_xml | – fundername: PHS HHS grantid: HHS0100200900106C |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP FBQ AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 |
| ID | FETCH-LOGICAL-c655t-b1755c0e396960ef696e57c7c808af6ce086649b578c69e0b4c68a03867714803 |
| IEDL.DBID | .~1 |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Thu Jul 10 21:21:20 EDT 2025 Fri Jul 11 14:51:43 EDT 2025 Fri Jul 11 04:06:04 EDT 2025 Wed Jul 30 11:01:39 EDT 2025 Wed Aug 13 06:00:15 EDT 2025 Thu Apr 03 07:07:26 EDT 2025 Wed Apr 02 07:21:53 EDT 2025 Thu Apr 24 23:09:51 EDT 2025 Tue Jul 01 03:38:05 EDT 2025 Thu Apr 03 09:44:10 EDT 2025 Fri Feb 23 02:26:54 EST 2024 Sun Feb 23 10:19:14 EST 2025 Tue Aug 26 16:33:16 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 48 |
| Keywords | H5N1 Adjuvants Vaccines Pandemic influenza Hemagglutinin Tropical zone Orthomyxoviridae Zoopathogen Vaccine Infection Virus Influenzavirus A Immunogenicity Avian influenzavirus Viral disease Immunological adjuvant Influenza |
| Language | English |
| License | CC BY 4.0 Copyright © 2013. Published by Elsevier Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c655t-b1755c0e396960ef696e57c7c808af6ce086649b578c69e0b4c68a03867714803 |
| Notes | http://dx.doi.org/10.1016/j.vaccine.2013.08.064 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| PMID | 24075920 |
| PQID | 1548831376 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | proquest_miscellaneous_1686710068 proquest_miscellaneous_1516756633 proquest_miscellaneous_1512336572 proquest_miscellaneous_1449268853 proquest_journals_1548831376 pubmed_primary_24075920 pascalfrancis_primary_27949104 crossref_citationtrail_10_1016_j_vaccine_2013_08_064 crossref_primary_10_1016_j_vaccine_2013_08_064 fao_agris_US201500179176 elsevier_sciencedirect_doi_10_1016_j_vaccine_2013_08_064 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X13011766 elsevier_clinicalkey_doi_10_1016_j_vaccine_2013_08_064 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-11-19 |
| PublicationDateYYYYMMDD | 2013-11-19 |
| PublicationDate_xml | – month: 11 year: 2013 text: 2013-11-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | CBER/FDA (bib0115) 2007 Imai, Watanabe, Hatta, Das, Ozawa, Shinya (bib0020) 2012; 486 Keitel, Treanor, El Sahly, Gilbert, Maeyer, Patricarca (bib0060) 2009; 28 Goji, Nolan, Hill, Wolff, Rowe, Treanor (bib0135) 2008; 198 S. Reed, Personal communication, 2011. Moris, Most, Leroux-Roels, Clement, Dramé, Hanon (bib0090) 2011; 31 Treanor, El Sahly, King, Graham, Izikson, Kohberger (bib0045) 2011; 39 Treanor, Wilkinson, Masseoud, Hu-Primmer, Battaglia, O’Brien (bib0075) 2001; 19 Herfst, Schrauwen, Linster, Chutinimitkul, de Wit, Munster (bib0015) 2012; 336 Beigel, Voell, Huang C-y, Burbelo, Lane (bib0120) 2009; 200 Treanor, Schiff, Hayden, Brady, Hay, Meyer (bib0040) 2007; 297 Baxter, Patriarca, Ensor, Izikson, Goldenthal, Cox (bib0055) 2011; 29 Tran, Nguyen, Nguyen, Luong, Pham, Nguyen (bib0005) 2004; 350 Uyeki, Timothy (bib0010) 2009; 49 Treanor, Schiff, Couch, Cate, Brady, Hay (bib0050) 2006; 193 Lopez, Caicedo, Sierra, Tilman, Banzhoff, Clemens (bib0130) 2011; 203 Coler, Bertholet, Moutaftsi, Guderian, Windish, Baldwin (bib0095) 2011; 6 Ehrlich, Müller, Fritsch, Zeitlinger, Berezuk, Löw-Baselli (bib0140) 2009; 200 Treanor, Campbell, Zangwill, Rowe, Wolff (bib0070) 2006; 354 Keitel, Campbell, Treanor, Walter, Patel, He (bib0065) 2008; 198 Wang, Holtz, Anderson, Chubet, Mahmoud, Cox (bib0035) 2006; 24 Lasko, Reich, Madan, Roman, Li, Vaughn (bib0125) 2011; 204 Baldwin, Shaverdian, Goto, Duthie, Raman, Evers (bib0100) 2009; 27 Cox, Hashimoto (bib0030) 2011; 107 Caillet, Piras, Bernard, de Montfort, Boudet, Vogel (bib0085) 2010; 20 Bernstein, Edwards, Dekker, Belshe, Talbot, Graham (bib0080) 2008; 197 Noah, Hill, Hines, White, Wolff (bib0110) 2009; 16 Russell, Fonville, Brown, Burke, Smith, James (bib0025) 2012; 336 Wang (10.1016/j.vaccine.2013.08.064_bib0035) 2006; 24 Lopez (10.1016/j.vaccine.2013.08.064_bib0130) 2011; 203 Tran (10.1016/j.vaccine.2013.08.064_bib0005) 2004; 350 Russell (10.1016/j.vaccine.2013.08.064_bib0025) 2012; 336 Treanor (10.1016/j.vaccine.2013.08.064_bib0075) 2001; 19 Uyeki (10.1016/j.vaccine.2013.08.064_bib0010) 2009; 49 Treanor (10.1016/j.vaccine.2013.08.064_bib0040) 2007; 297 Caillet (10.1016/j.vaccine.2013.08.064_bib0085) 2010; 20 Treanor (10.1016/j.vaccine.2013.08.064_bib0070) 2006; 354 Bernstein (10.1016/j.vaccine.2013.08.064_bib0080) 2008; 197 CBER/FDA (10.1016/j.vaccine.2013.08.064_bib0115) 2007 Herfst (10.1016/j.vaccine.2013.08.064_bib0015) 2012; 336 Keitel (10.1016/j.vaccine.2013.08.064_bib0065) 2008; 198 Lasko (10.1016/j.vaccine.2013.08.064_bib0125) 2011; 204 Treanor (10.1016/j.vaccine.2013.08.064_bib0045) 2011; 39 Treanor (10.1016/j.vaccine.2013.08.064_bib0050) 2006; 193 Ehrlich (10.1016/j.vaccine.2013.08.064_bib0140) 2009; 200 Baxter (10.1016/j.vaccine.2013.08.064_bib0055) 2011; 29 Coler (10.1016/j.vaccine.2013.08.064_bib0095) 2011; 6 Beigel (10.1016/j.vaccine.2013.08.064_bib0120) 2009; 200 10.1016/j.vaccine.2013.08.064_bib0105 Keitel (10.1016/j.vaccine.2013.08.064_bib0060) 2009; 28 Goji (10.1016/j.vaccine.2013.08.064_bib0135) 2008; 198 Imai (10.1016/j.vaccine.2013.08.064_bib0020) 2012; 486 Moris (10.1016/j.vaccine.2013.08.064_bib0090) 2011; 31 Baldwin (10.1016/j.vaccine.2013.08.064_bib0100) 2009; 27 Cox (10.1016/j.vaccine.2013.08.064_bib0030) 2011; 107 Noah (10.1016/j.vaccine.2013.08.064_bib0110) 2009; 16 |
| References_xml | – volume: 197 start-page: 667 year: 2008 end-page: 675 ident: bib0080 article-title: Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults publication-title: J Infect Dis – volume: 107 start-page: S31 year: 2011 end-page: S41 ident: bib0030 article-title: A fast track influenza virus vaccine produced in insect cells publication-title: J Invertebr Pathol – volume: 200 start-page: 501 year: 2009 end-page: 509 ident: bib0120 article-title: Safety and Immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine publication-title: J Infect Dis – volume: 39 start-page: 7733 year: 2011 end-page: 7739 ident: bib0045 article-title: Protective efficacy of a trivalent, recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial publication-title: Vaccine – volume: 204 start-page: 574 year: 2011 end-page: 581 ident: bib0125 article-title: Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults publication-title: J Infect Dis – volume: 200 start-page: 1113 year: 2009 end-page: 1118 ident: bib0140 article-title: A cell-culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses publication-title: J Infect Dis – volume: 203 start-page: 1719 year: 2011 end-page: 1728 ident: bib0130 article-title: Combined, concurrent and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized controlled trial of immunogenicity and safety in healthy adults publication-title: J Infect Dis – volume: 198 start-page: 635 year: 2008 end-page: 641 ident: bib0135 article-title: Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/04 (H5N1) vaccine after priming with an antigenic variant publication-title: J Infect Dis – volume: 28 start-page: 379 year: 2009 end-page: 385 ident: bib0060 article-title: Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons ≥65 years old publication-title: Vaccine – volume: 24 start-page: 2176 year: 2006 end-page: 2185 ident: bib0035 article-title: Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine publication-title: Vaccine – volume: 354 start-page: 1343 year: 2006 end-page: 1351 ident: bib0070 article-title: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine publication-title: N Engl J Med – volume: 19 start-page: 1732 year: 2001 end-page: 1737 ident: bib0075 article-title: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine publication-title: Vaccine – volume: 31 start-page: 443 year: 2011 end-page: 454 ident: bib0090 article-title: H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses publication-title: J Clin Immunol – volume: 20 start-page: 3076 year: 2010 end-page: 3079 ident: bib0085 article-title: AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice publication-title: Vaccine – volume: 6 start-page: e16333 year: 2011 ident: bib0095 article-title: Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant publication-title: PLoS ONE – volume: 49 start-page: 279 year: 2009 end-page: 290 ident: bib0010 article-title: Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues publication-title: Clin Infect Dis – volume: 297 start-page: 1577 year: 2007 end-page: 1582 ident: bib0040 article-title: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial publication-title: JAMA – volume: 16 start-page: 558 year: 2009 end-page: 566 ident: bib0110 article-title: Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure publication-title: Clin Vaccine Immunol – volume: 350 start-page: 1179 year: 2004 end-page: 1188 ident: bib0005 article-title: Avian influenza A (H5N1) in 10 patients in Vietnam publication-title: N Engl J Med – year: 2007 ident: bib0115 article-title: Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccine. s.l.: DHHS/FDA/CBER – volume: 336 start-page: 1541 year: 2012 end-page: 1547 ident: bib0025 article-title: The potential for respiratory droplet-transmissable A/H5N1 influenza virus to evolve in a mammalian host publication-title: Science – volume: 198 start-page: 1309 year: 2008 end-page: 1319 ident: bib0065 article-title: Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I/II randomized clinical trial publication-title: J Infect Dis – volume: 486 start-page: 420 year: 2012 end-page: 428 ident: bib0020 article-title: Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets publication-title: Nature – volume: 29 start-page: 2272 year: 2011 end-page: 2278 ident: bib0055 article-title: Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age publication-title: Vaccine – reference: S. Reed, Personal communication, 2011. – volume: 27 start-page: 5956 year: 2009 end-page: 5963 ident: bib0100 article-title: Enhanced humoral and Type 1 cellular immune responses with Fluzone publication-title: Vaccine – volume: 336 start-page: 1534 year: 2012 end-page: 1541 ident: bib0015 article-title: Airborne transmission of influenza A/H5N1 virus between ferrets publication-title: Science – volume: 193 start-page: 1223 year: 2006 end-page: 1228 ident: bib0050 article-title: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults publication-title: J Infect Dis – volume: 29 start-page: 2272 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0055 article-title: Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age publication-title: Vaccine doi: 10.1016/j.vaccine.2011.01.039 – volume: 28 start-page: 379 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0060 article-title: Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons ≥65 years old publication-title: Vaccine doi: 10.1016/j.vaccine.2009.10.037 – volume: 297 start-page: 1577 year: 2007 ident: 10.1016/j.vaccine.2013.08.064_bib0040 article-title: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.297.14.1577 – volume: 200 start-page: 1113 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0140 article-title: A cell-culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses publication-title: J Infect Dis doi: 10.1086/605608 – volume: 336 start-page: 1534 year: 2012 ident: 10.1016/j.vaccine.2013.08.064_bib0015 article-title: Airborne transmission of influenza A/H5N1 virus between ferrets publication-title: Science doi: 10.1126/science.1213362 – volume: 107 start-page: S31 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0030 article-title: A fast track influenza virus vaccine produced in insect cells publication-title: J Invertebr Pathol doi: 10.1016/j.jip.2011.05.003 – volume: 49 start-page: 279 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0010 article-title: Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues publication-title: Clin Infect Dis doi: 10.1086/600035 – volume: 39 start-page: 7733 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0045 article-title: Protective efficacy of a trivalent, recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial publication-title: Vaccine doi: 10.1016/j.vaccine.2011.07.128 – volume: 24 start-page: 2176 year: 2006 ident: 10.1016/j.vaccine.2013.08.064_bib0035 article-title: Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2005.11.005 – ident: 10.1016/j.vaccine.2013.08.064_bib0105 – volume: 203 start-page: 1719 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0130 article-title: Combined, concurrent and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized controlled trial of immunogenicity and safety in healthy adults publication-title: J Infect Dis doi: 10.1093/infdis/jir191 – volume: 6 start-page: e16333 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0095 article-title: Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant publication-title: PLoS ONE doi: 10.1371/journal.pone.0016333 – volume: 193 start-page: 1223 year: 2006 ident: 10.1016/j.vaccine.2013.08.064_bib0050 article-title: Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults publication-title: J Infect Dis doi: 10.1086/503050 – volume: 27 start-page: 5956 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0100 article-title: Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion publication-title: Vaccine doi: 10.1016/j.vaccine.2009.07.081 – volume: 197 start-page: 667 year: 2008 ident: 10.1016/j.vaccine.2013.08.064_bib0080 article-title: Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults publication-title: J Infect Dis doi: 10.1086/527489 – volume: 350 start-page: 1179 year: 2004 ident: 10.1016/j.vaccine.2013.08.064_bib0005 article-title: Avian influenza A (H5N1) in 10 patients in Vietnam publication-title: N Engl J Med doi: 10.1056/NEJMoa040419 – volume: 486 start-page: 420 year: 2012 ident: 10.1016/j.vaccine.2013.08.064_bib0020 article-title: Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets publication-title: Nature doi: 10.1038/nature10831 – volume: 198 start-page: 635 year: 2008 ident: 10.1016/j.vaccine.2013.08.064_bib0135 article-title: Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/04 (H5N1) vaccine after priming with an antigenic variant publication-title: J Infect Dis doi: 10.1086/590916 – volume: 198 start-page: 1309 year: 2008 ident: 10.1016/j.vaccine.2013.08.064_bib0065 article-title: Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I/II randomized clinical trial publication-title: J Infect Dis doi: 10.1086/592172 – volume: 31 start-page: 443 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0090 article-title: H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses publication-title: J Clin Immunol doi: 10.1007/s10875-010-9490-6 – volume: 20 start-page: 3076 year: 2010 ident: 10.1016/j.vaccine.2013.08.064_bib0085 article-title: AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice publication-title: Vaccine doi: 10.1016/j.vaccine.2010.02.050 – year: 2007 ident: 10.1016/j.vaccine.2013.08.064_bib0115 – volume: 354 start-page: 1343 year: 2006 ident: 10.1016/j.vaccine.2013.08.064_bib0070 article-title: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa055778 – volume: 16 start-page: 558 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0110 article-title: Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure publication-title: Clin Vaccine Immunol doi: 10.1128/CVI.00368-08 – volume: 200 start-page: 501 year: 2009 ident: 10.1016/j.vaccine.2013.08.064_bib0120 article-title: Safety and Immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine publication-title: J Infect Dis doi: 10.1086/599992 – volume: 336 start-page: 1541 year: 2012 ident: 10.1016/j.vaccine.2013.08.064_bib0025 article-title: The potential for respiratory droplet-transmissable A/H5N1 influenza virus to evolve in a mammalian host publication-title: Science doi: 10.1126/science.1222526 – volume: 19 start-page: 1732 year: 2001 ident: 10.1016/j.vaccine.2013.08.064_bib0075 article-title: Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine publication-title: Vaccine doi: 10.1016/S0264-410X(00)00395-9 – volume: 204 start-page: 574 year: 2011 ident: 10.1016/j.vaccine.2013.08.064_bib0125 article-title: Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults publication-title: J Infect Dis doi: 10.1093/infdis/jir328 |
| SSID | ssj0005319 |
| Score | 2.387822 |
| Snippet | •We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE.•Adjuvanted vaccine was substantially more immunogenic at all... Highlights • We evaluated baculovirus-expressed recombinant H5 hemagglutinin vaccine with the adjuvant GLE/SE. • Adjuvanted vaccine was substantially more... BACKGROUND: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the... Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the potential for a... Background Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the... Background: Expression of recombinant hemagglutinin (rHA) in insect cells represents a technology with proven efficacy in seasonal influenza and with the... |
| SourceID | proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 5760 |
| SubjectTerms | Adjuvants Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - adverse effects Adolescent Adult adults Allergy and Immunology Animals Antibodies, Viral - blood Antigens Applied microbiology Avian flu Baculovirus Biological and medical sciences blood serum Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - pathology Emergency medical care Emulsions Emulsions - administration & dosage Emulsions - adverse effects Female Fundamental and applied biological sciences. Psychology H5N1 Healthy Volunteers hemagglutination Hemagglutination Inhibition Tests Hemagglutinin Glycoproteins, Influenza Virus - genetics Hemagglutinin Glycoproteins, Influenza Virus - immunology hemagglutinins Hospitalization Humans Hydration Immunization Immunogenicity influenza Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology injection site Insects Licenses lipid A Lipid A - administration & dosage Lipid A - adverse effects Lipid A - analogs & derivatives Lipids Male Microbiology Middle Aged Miscellaneous Mortality Mutation Pain pandemic Pandemic influenza Pandemics Placebos - administration & dosage Proteins recombinant DNA Recombinant Proteins - genetics Recombinant Proteins - immunology Studies Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology Virology Viruses Young Adult |
| SummonAdditionalLinks | – databaseName: ProQuest Health & Medical Collection (NC LIVE) dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1tb9MwELbYEIgvCMrLAmMyEpo2sazOi53kE6pQR0EMTeqG-s1yEqdKVZKypKDyO_lB3OVVSKzjSxU1viS2zufn7LvnCHkTBVZi2UqYthMm4KAwbqpY26arAs6RP8yqEmnPv4jJlftpxmfNhlvRhFW2NrEy1HEe4R75EKG171gwH96tvptYNQpPV5sSGjvkLlKXoVZ7M68P8XCqwh7gZrima7FZn8EzXJz-UBEeXWN0l1OzeLo3rU07icoxaFIVMG5JXfDiZkRarUxnj8jDBlLSUa0Dj8kdnQ3IvbrI5GZA7p83x-cDcnhRE1VvTuhln3dVnNBDetFTWIPM4CtGyVSpurQVf0J-jztqcJontFCJLjdUZTFNMcskB12ElvAX3ERH-1tYhdnQtC6E8ktRZIidz1HZszSjRxM-_IjVRHSRqiHjQ9x7OqYIo7GomI4p7hJXL8CLfF1SRQHNhktN83Rpppn5E5pdUw3tcdePYuB9XfKCVrH4qw0MY15sluYyXaUxHdGj6fjth8-jY6rixRq8iPIpuTobX76fmE1VCDMSnJdmCICHR0w7yOvDdAK_mnuRF_nMV4mINDhpwg1CMEWRCDQL3Uj4ijlI3Ae-H3Oekd0MerZHKFIFhT54nFz5yCOHVw6AhjDhSiilDOK2-iCjhjIdK3csZRsbt5CNGklUI4kVPYVrkNNObFVzhtwmIFplk21CLJhwCavabYLevwR10RiiQlqysCWTU1YBXzaz0KB7QhjE7yQbrFVjqP956R7MB6nmsArJq6mNe2Zo1-GxBjn4a5J03bfB7AMwBdn9dtbI_hu7qW2Q191tMHN4dqUyna-hjYvMlj6Ayy1tALw6juCevbUNuMgAs7c9RyDpIyZPGeR5PbP7jriAsQObvdjekZfkAY4YJq1awT7ZLa_X-hWg1zI8qEzUH8rVl0c priority: 102 providerName: ProQuest |
| Title | Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X13011766 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X13011766 https://dx.doi.org/10.1016/j.vaccine.2013.08.064 https://www.ncbi.nlm.nih.gov/pubmed/24075920 https://www.proquest.com/docview/1548831376 https://www.proquest.com/docview/1449268853 https://www.proquest.com/docview/1512336572 https://www.proquest.com/docview/1516756633 https://www.proquest.com/docview/1686710068 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfGEIgXBAW2wpiMhKZNLM2nneSxVB0dsKqiK-qb5aROlaok1ZKCygN_JX8Qd_lomWAd4iV1k7skts7nO-fud4S8Dn0zMi3JNcsOInBQDKbJibI0R_qMIX6YWSTSXvR5b-S8H7PxDunUuTAYVlnp_lKnF9q6OqNXo6kv4lgfGsVaboxNlFGXI-y247go5a0fv4V52EVxDyTWkHqTxaPPWl9liJ-vMcLLLpE8nZvWpzuRTDFwUmYwdlFZ9OJmq7RYnc4ekYeVWUnb5Zs_JjsqaZB7ZaHJVYPcv6g-oTfI0aAEq16d0stN7lV2So_oYANjDTyNzxgpU6Tr0pr9CfnZXcOD0zSimYxUvqIymdAYM01SkEeghFNwEZ3tL0ERakPjshjKd0kRJXY6RYFP4oQe95h-jhVFVBZL3WA67j-dUDSlsbCYmlDcKS4egI10mVNJwaIN5oqm8VyLE-0bkF1RBfS480cx-L4se0GLePzFCoYxzVZzbR4v4glt0-Nh9827j-0TKiezJXgS-VMyOutednpaVRlCCzljuRaA0cNCQ9mI7WOoCI6KuaEbeoYnIx4qcNS44wegjkLuKyNwQu5Jw0bwPvD_DPsZ2U2gZ_uEIlxQ4IHXyaSHWHLYssFwCCImuZSySZxaHkRYwaZj9Y65qOPjZqISI4FiJLCqJ3eapLVmW5S4Ibcx8FrYRJ0UC2pcwMp2G6P7N0aVVcooE6bILGGIPyZMk3hrzmtz7l8eug_zQcgprERiNLRw3wx1O9y2SQ6vTZJ19y1Q_WCcAu9BPWvE5h3Bc_Zs00b-V-vLoOrw-5VMVLoEGgfRLT0wMLfQgAFr25y51lYacJPB1N52H47Aj5hA1SR75czedMQBO9u3jOf_P34vyAP8h0mtpn9AdvOrpXoJ1m0eHBbqC47u2IWj14H23fb5h14fft92-4NPvwD30KZC |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF21RVxeEIRLA6UMElStqJv1ZTfOA0JRaUnpRZXaorwta2ddOQp2qBOq8FF8DR_EjC8JSDTlpS-RFe_YXnt258zuzBnGXoctO7IdLS3HDSJ0ULiwdM84lqdbQhB_mJ0n0h4eyc6Z96krugvsZ5ULQ2GV1ZyYT9S9NKQ18gZBa9-1cTy8H36zqGoU7a5WJTQKtdg3k0t02bJ3ex_w-75xnN2d0-2OVVYVsEIpxMgK0GCKkBuXeGG4ifDXiGbYDH3u60iGBkG-9FoBqnIoW4YHXih9zV0ifkPfgbt43UV2y3PxUSgzffuPkBI3LySCbo1neTbvzjKGGv2t7zqkrXKKJnML1lDvKlu4GOmUgjR1ht8pKgpsXI2Ac0u4-4DdLyEstAude8gWTFJjt4uilpMau3NYbtfX2NpxQYw92YTTWZ5XtglrcDyjzEaZ2meKyslTg6ESf8R-7UypyCGNINORGU1AJz2IKaslRd3HlvgXniTH_muQh_VAXBRe-aGBGGnPz2lwJXEC6x3R2KPqJSaLdYOLBq11bQDBdipiZnpAq9L5DeggHY9AA6LnYGAgjQdWnFiX2OwCDLanVUagQP-ixAbksf_DCb7GNJsMrEE8jHvQhvWTnbcfD9oboHv9MXoto8fs7Eb05QlbSrBnywyImijw0cMV2ifeOjpyEaQEkdBSa11nXqUPKiwp2qlSyEBVsXh9VaqRIjVSVEFUenW2NRUbFhwl1wnIStlUlYCLJkOhFb1OsPkvQZOVE1-mbJU5iqsTngNt3rXJgDSlrDN_KlliuwKz_c9Nl3E8KH2OVk-dnTi0Rkd2BC9bZ6t_DZJp9x00MwiEUXalGjVq9ozTqaTOXk1P47RKe2U6MekY23jEpOkjmJ3TBsGy60rRdOa2QZccYf2860gimaRkrTp7WozsWUc8xPQthz-b35GX7G7n9PBAHewd7T9n9-jtUcKs3VphS6OLsXmByHkUrObTFbAvNz0__gZhmNHc |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEF61RVS8IAhHA6UMElStWjfrY9fOA0JVD1p6qFJblLdl7awrV8EOdUIVfhq_gx_EjI8EJJry0pfIindsrz3HN7tzMPY2atux7WhpOW4Yo4PChaW7xrE83RaC6ofZRSLt0bHcO_c-dURnhv2sc2EorLLWiYWi7mYRrZG3CFoHro3y0IqrsIiT7d0P_W8WdZCinda6nUbJIgdmdI3uW_5-fxu_9TvH2d0529qzqg4DViSFGFghGk8RceNSjRhuYvw1wo_8KOCBjmVkEPBLrx0iW0eybXjoRTLQ3KUicOhHcBevO8vu-a4fkIwFW3-El7hFUxF0cTzLs3lnkj3Uutz4riPaNqfIMresIOrdZBdnY51RwKbO8ZvFZbONm9FwYRV3H7GHFZyFzZL_HrMZkzbY_bLB5ajB5o-qrfsGWz4pi2SP1uFskvOVr8MynEzKZyNN4zNF6BRpwlCTP2G_dsZlySGLIdexGYxAp11IKMMlQznAkfgXniQn_2tYhPhAUjZh-aGBqtNeXJCgpUkKK3uitU-dTEye6BYXLVr3WgWC8NTQzHSBVqiLG9BBNhyABkTSYc9AlvSsJLWucdgVGBxPK45AQf9luw0o8gD6I3yNWT7qWb2kn3RhE1ZOd9Y-Hm6ugu5eDtGDGTxl53fCL8_YXIozW2BAZYrCAL1doQOqYUdHLgKWMBZaaq2bzKv5QUVVuXbqGtJTdVzeparYSBEbKeomKr0m2xiT9ct6JbcRyJrZVJ2Mi-ZDoUW9jdD_F6HJKyWYK1vljuLqlBegm3dsMia-lE0WjCkrnFfit_-56QLKg9IXaAHV-alD63VkU_CyTbb0l5CMp--gyUFQjLSLtdSoyTOO1UqTvRmfRhVL-2Y6NdkQx3hUVTNAYDtlDAJn15XCd6aOQfccIf6060gqOEmJW032vJTsyUQ8xPdth7-YPpHXbB41ozrcPz54yR7Qy6PcWbu9yOYGV0PzCkH0IFwqtBWwL3etHn8DozjWEg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+safety+and+immunogenicity+of+recombinant+influenza+hemagglutinin+%28H5%2FIndonesia%2F05%2F2005%29+formulated+with+and+without+a+stable+oil-in-water+emulsion+containing+glucopyranosyl-lipid+A+%28SE%2BGLA%29+adjuvant&rft.jtitle=Vaccine&rft.au=Treanor%2C+John+J&rft.au=Essink%2C+Brandon&rft.au=Hull%2C+Steven&rft.au=Reed%2C+Steven&rft.date=2013-11-19&rft.issn=1873-2518&rft.eissn=1873-2518&rft.volume=31&rft.issue=48&rft.spage=5760&rft_id=info:doi/10.1016%2Fj.vaccine.2013.08.064&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X13X00544%2Fcov150h.gif |